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Since Edward Jenner' s discovery of the basic concept
of vaccination in 1796, vaccines have become a critical
component of our armamentarium for preventing a broad
spectrum of infectious diseases. Vaccination now sits at
center stage in our ability to impact public health on a
global scale, and, aside from sanitation and clean water,
represents one of the easiest and most cost-effective
means to control infectious diseases and improve people' s
standards of life.
The beneficial impact of vaccination extends beyond
protection of the individual --- also it gives rise to “herd
immunity,” an effect whereby vaccination of a large pro-
portion of the population hinders the transmission of an
infectious agent and thereby protects the entire popula-
tion, even those not vaccinated.1 Indeed, this effect has
led to some remarkable results, including eradication of
smallpox and virtual disappearance of diphtheria, tetanus,
and paralytic poliomyelitis.1 However, it is clear that much
remains to be accomplished to close the global vaccination
gap2 and to reduce the annual toll of approximately 3
million children dying from vaccine-preventable diseases.3
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As the science of vaccinology enters its third millen-
nium, it is appropriate to reflect on some of the current
key trends in the global vaccine scene. Advances in molec-
ular biology have led to monumental leaps in vaccine
development,4 and, in this regard, several new scien-
tific capabilities are particularly noteworthy: reassortment
technology, virus-like particles (VLPs), and recombinant
subunit vaccines. Reassortment technology is especially
useful for developing vaccines against organisms that exist
as multiple different subtypes, usually with segmented
genomes (e.g., rotaviruses).5 The process involves substi-
tuting gene sequences from human into animal viruses to
generate reassorted progeny strains that are nonvirulent
to humans, but nevertheless elicit a protective immune
response to multiple strains. Another remarkable advance
has been the application of recombinant DNA technology to
create novel VLPs. This technology has been applied for the
first time to develop human papillomavirus (HPV) vaccines
devoid of the entire HPV genome, thereby avoiding the
potential exposure of people to viral oncogenes.6,7 These
VLPs elicit high-titers of virus neutralizing antibodies and
other protective HPV-specific immune responses.6,8
We also are witnessing a paradigm shift in the clinical
evaluation of vaccines. The introduction of more stringent
national and international regulatory requirements for the
clinical characterization of vaccines, together with greater
emphasis on vaccine safety, has ushered in the era of the
mega trial (more than 70,000 infants were enrolled in a
recent rotavirus vaccine trial).9 These trials enroll many
tens of thousands of subjects and also sometimes employ
surrogate endpoints (e.g., CIN 2/3 as a surrogate endpoint
for cervical cancer in HPV vaccine trials). In addition,
studies are now more frequently conducted in a much
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broader spectrum of individuals. In the past, immunization
has traditionally focused on infants and young children, but
it is now clear that other target populations might benefit
from certain vaccines, including adolescents and young
adults, the elderly and, immunocompromised patients.4
Clinical evaluation is also taking place of vaccines directed
toward infectious agents that could potentially be used in
bioterrorist attacks (e.g., anthrax and vaccinia).4
The renewed global interest in vaccines in recent years
is evidenced by the formation of GAVI Alliance (formerly
known as the Global Alliance for Vaccines and Immu-
nization) in 2000.3 The GAVI Alliance is a collaborative
venture between public and private sectors with the goal
of bringing the benefits of immunization to children who
are in the greatest need. The cornerstone of the GAVI
Alliance' s mission is the belief that all children --- no matter
where they live --- deserve a healthy start. Working through
the GAVI Alliance, the International Finance Facility for
Immunization (IFFIm10) and other new funding mechanisms
are accelerating the availability of funds for health and
immunization programs to many of the world' s poorest
countries. The increased global demand for vaccines has
resulted in a substantially enlarged manufacturing base
that now includes production capabilities in mid-developed
countries such as India and China.
Despite the remarkable achievements in vaccine re-
search and development, and a renewed interest in the
global public health benefits of vaccination, a number
of major roadblocks remain. Foremost is the existence
of a narrow base for discovery and development of new
vaccines, a situation linked, in part, to the enormous costs
associated with research, development, manufacture, and
launch of new vaccines. These costs are so large ($ 400 to
800 million per vaccine1) that only the largest international
pharmaceutical companies can shoulder the burden. Since
economic principles dictate that companies price their
products according to the level of investment made, this
has led to the unevenness of deployment of vaccines be-
tween the developed and developing world. This disparity
is being addressed immediately. Some partial solutions
include: differential pricing of vaccines; highlighting that
local costs of vaccines can be more than offset by long-
term national healthcare savings; and by promoting and
supporting public-private partnerships that purchase and
distribute vaccines to poorer nations.
In addition to GAVI Alliance, World Health Organization
and UNICEF, other global and national champions for
immunization are urgently needed to take a strong stand
on the need to realize the full potential of vaccines to
relieve human misery. One of their key goals should be
to counter the anti-vaccination campaigns that seriously
impede immunization efforts in both developed and
developing countries. Another goal must be to improve
the infrastructure for vaccination programs, especially in
developing countries. While an adequate infrastructure
will invariably be complex and costly, it is crucial for en-
suring the optimal delivery of vaccines, preventing vaccine
shortages, conducting outreach and education programs,
maintaining coverage rates, and addressing control of
outbreaks.
While many problems remain in terms of vaccine pro-
duction, regulation, distribution, and funding, it is clear
that exciting new research and discovery tools are now
available, and that these are likely to lead to introduction
of new vaccines to prevent more human disease. The pur-
pose of this supplement is to highlight four new vaccines ---
quadrivalent HPV (types 6, 11, 16, 18) vaccine, pentavalent
human-bovine reassortant rotavirus vaccine, herpes zoster
vaccine, and pediatric quadrivalent vaccine for measles,
mumps, rubella, and varicella --- that have arisen, in part,
from the creative application of some of these powerful
new techniques.
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